巴匹珠单抗3期随机临床试验中ARIA-E参与者的生物标志物模式
研究评估巴匹珠单抗临床试验中淀粉样蛋白相关影像学异常伴水肿/积液(ARIA-E)是否与特定生物标志物模式相关。1,512名参与者接受生物标志物评估,154例发生ARIA-E。基线生物标志物大多不能预测ARIA-E风险,但ARIA-E与多个生物标志物的纵向变化显著相关。
要点
- 基线淀粉样蛋白PET、多数vMRI指标及脑脊液生物标志物在ARIA-E与非ARIA-E组间无差异。
- 第71周时,巴匹珠单抗治疗且发生ARIA-E者较非ARIA-E者脑淀粉样蛋白PET降低更明显,脑脊液p-tau和t-tau下降更显著。
- ARIA-E与海马体积缩小和脑室扩大更明显相关,提示ARIA-E可能与Aβ从脑内流出增加有关。
核心结论
- 基线生物标志物在很大程度上不能预测发生ARIA-E的风险。
- ARIA-E与多个生物标志物的显著纵向变化相关,包括淀粉样蛋白PET和脑脊液p-tau、t-tau浓度降低更明显,以及 paradoxical 更明显的海马体积缩小和脑室扩大,提示巴匹珠单抗治疗病例中的ARIA-E可能与Aβ从脑内流出增加并影响下游致病过程有关。
研究设计与样本
- 巴匹珠单抗3期随机临床试验,评估轻至中度阿尔茨海默病患者,进行淀粉样蛋白PET成像、脑脊液生物标志物或容积MRI评估。
- 共1,512名参与者接受至少一项生物标志物评估,其中154例发生ARIA-E。
主要发现
- 基线时,ARIA-E与非ARIA-E参与者在脑淀粉样蛋白负荷(PET)、多数vMRI指标或脑脊液生物标志物方面无差异,例外为APOE ε4非携带者中ARIA-E组基线脑脊液Aβ42较低(巴匹珠单抗非ARIA-E组 p=0.027;安慰剂非ARIA-E组 p=0.012)。
- 第71周时,巴匹珠单抗治疗且发生ARIA-E者较非ARIA-E者显示脑淀粉样蛋白PET降低更明显、脑脊液磷酸化tau(p-tau)降低更明显(所有比较 p<0.01)、总tau(t-tau)降低更明显(所有比较 p<0.025),以及海马体积缩小和脑室扩大更明显(所有 p<0.05)。
- ARIA-E组较两个非ARIA-E组脑脊液Aβ40浓度降低更明显(巴匹珠单抗非ARIA-E组 p=0.015,安慰剂非ARIA-E组 p=0.049)。
- 第71周时,全脑体积变化或脑脊液Aβ42变化在各组间无差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether amyloid-related imaging abnormalities with edema/effusion (ARIA-E) observed in bapineuzumab clinical trials was associated with specific biomarker patterns. METHODS: Bapineuzumab, an anti-β-amyloid monoclonal antibody, was evaluated in patients with mild to moderate Alzheimer disease. Amyloid PET imaging, CSF biomarkers, or volumetric MRI (vMRI) were assessed. RESULTS: A total of 1,512 participants underwent one or more biomarker assessments; 154 developed incident ARIA-E. No differences were observed at baseline between ARIA-E and non-ARIA-E participants in brain amyloid burden by PET, the majority of vMRI measures, or CSF biomarkers, with the exception of lower baseline CSF Aβ42 in APOE ε4 noncarrier ARIA-E vs non-ARIA-E groups (bapineuzumab non-ARIA-E p = 0.027; placebo non-ARIA-E p = 0.012). At week 71, bapineuzumab-treated participants with ARIA-E vs non-ARIA-E showed greater reduction in brain amyloid PET, greater reductions in CSF phosphorylated tau (p-tau) (all comparisons p < 0.01), and total tau (t-tau) (all comparisons p < 0.025), and greater hippocampal volume reduction and ventricular enlargement (all p < 0.05). Greater reduction in CSF Aβ40 concentrations was observed for ARIA-E versus both non-ARIA-E groups (bapineuzumab/placebo non-ARIA-E p = 0.015/0.049). No group differences were observed at week 71 for changes in whole brain volume or CSF Aβ42. CONCLUSIONS: Baseline biomarkers largely do not predict risk for developing ARIA-E. ARIA-E was associated with significant longitudinal changes in several biomarkers, with larger reductions in amyloid PET and CSF p-tau and t-tau concentrations, and paradoxically greater hippocampal volume reduction and ventricular enlargement, suggesting that ARIA-E in bapineuzumab-treated cases may be related to increased Aβ efflux from the brain and affecting downstream pathogenic processes.
引用
- Liu E, Wang D, Sperling R, et al. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. Neurology. 2018. PMID: 29429971. doi:10.1212/WNL.0000000000005060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。